IMD - Institut für Medizinische Diagnostik launches the GA-map® Microbiome Test in Germany
OSLO, NORWAY/BERLIN, GERMANY – 15 February 2022: Microbiome DX company Genetic Analysis AS (“GA”) and Institut für Medizinische Diagnostik (“IMD”), a part of the Medicover Group, announces today that IMD has launched the GA-map® Dysbiosis Test in Germany. IMD will activate its new Microbiome laboratory in February 2022 and add standardized microbiota testing to its existing test portfolio of products. This new Microbiota test offering will be marketed to customers in Germany and Europe.In 2021, Genetic Analysis launched the updated version of GA-map[®] Dysbiosis Test – the first CE-marked